Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography

Otto S. Hoekstra*, Arthur van Lingen, Gert J. Ossenkoppele, Richard Golding, Gerrit J.J. Teule

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Metabolic response monitoring early during chemotherapy may have a major impact on clinical management of patients with malignant lymphoma. In two patients with non-Hodgkin's lymphoma fluorine-18 fluorodeoxyglucose (IgFDG) single-photon emission tomography (SPET) studies were performed during the first two chemotherapeutic cycles. Persisting uptake predicted treatment failure whereas a sharp reduction of 18FDG uptake was demonstrated in the case of a responsive tumour. Qualitative analysis of conventional 18FDG imaging may thus serve to identify patients with a non-responding tumour. The potential of this technique in the determination of the initial response remains to be established. Imaging with 18FDG and SPET appears promising as a more easily available methodology than 18FDG positron emission tomography.

Original languageEnglish
Pages (from-to)1214-1217
Number of pages4
JournalEuropean Journal of Nuclear Medicine
Issue number12
Publication statusPublished - Dec 1993

Cite this